Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF0O3X)

• Drug Name: MCLA-158 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMF0O3X

Molecule-Related Drug Atlas

Drug(s) Targeting Leucine-rich repeat-containing GPCR 5 (LGR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BNC-101	DMSBM6A	Metastatic colorectal cancer	2B91	Phase 1	[3]
BNC-102	DMM1O0P	Solid tumour/cancer	2A00-2F9Z	Preclinical	[4]
KM-4056	DMK17GN	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[6]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[7]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[8]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[9]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[10]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[11]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[12]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[13]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[11]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[2]
Leucine-rich repeat-containing GPCR 5 (LGR5)	TTTSGRH	LGR5_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03526835) A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Merus.
• [3] Clinical pipeline report, company report or official report of Bionomics.
• [4] Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 148).
• [6] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [7] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [8] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [9] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [10] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [12] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [13] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [14] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).